SYMBERIX, INC. — Department of Health and Human Services SBIR Phase I: NCI
SYMBERIX, INC. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $268,641
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NCI
- NAICS
- —
- Place of performance
- NC
- Period
- —
Description
A sugar scavenging bacterial enzyme glucuronidase bGUS in the GI microbiome is responsible for the dangerous diarrheal side effects of irinotecan an anti neoplastic agent used to treat advanced colorectal and pancreatic cancers Irinotecan which is rendered inactive in the liver by the attachment of a glucuronide sugar is reactivated by bGUS mediated cleavage of the glucuronide sugar in the lower GI microflora Reactivated irinotecan is highly toxic and damages nearby intestinal cells resulting in intense dose limiting diarrhea The goal of this project is to determine if bacterial bGUS which exists as a number of different enzyme orthologues in the GI microbiome is also involved in severe diarrheal side effects associated with another class of anti cancer drugs tyrosine kinase inhibitors TKIs